MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide first identified in 2015 by Changhan David Lee and colleagues at the University of Southern California. What makes MOTS-c scientifically unusual is its origin: unlike the vast majority of peptides, it is encoded within the mitochondrial genome — specifically within the 12S ribosomal RNA (rRNA) region — rather than in the nuclear DNA that encodes most cellular proteins.

MOTS-c belongs to a newly recognized class of signaling molecules called mitochondria-derived peptides (MDPs). MDPs are small peptides encoded by short open reading frames within mitochondrial DNA that appear to function as hormones or cellular signals — communicating mitochondrial stress status to the rest of the cell and to other tissues. Other MDPs include Humanin (discovered 2001) and SHLP2, SHLP3, SHLP4, SHLP5, and SHLP6 (discovered 2016).

MOTS-c has been shown in preclinical models to activate AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. AMPK activation is associated with improved insulin sensitivity, enhanced fatty acid oxidation, mitochondrial biogenesis, and a reduction in inflammatory signaling. In animal models, MOTS-c behaves as an "exercise mimetic" — producing some of the same metabolic adaptations seen with physical activity, without the physical exercise itself.

MOTS-c circulates in human plasma and cerebrospinal fluid. Circulating MOTS-c levels decline with age in humans and are lower in individuals with insulin resistance, type 2 diabetes, and metabolic disease — observations that have driven interest in MOTS-c as both a biomarker and a potential therapeutic target.

Evidence and regulatory caution: Human clinical trial data for MOTS-c as an intervention is extremely limited. The bulk of research consists of animal studies (mice, primarily) and in-vitro cell models. MOTS-c is currently classified by the FDA as a Category 2 substance (not eligible for compounding), although a reclassification announcement was made in February 2026 (see Legal Status section). Any discussion of MOTS-c benefits must be understood in the context of predominantly preclinical evidence.

MOTS-c exerts its effects primarily through activation of AMP-activated protein kinase (AMPK) and related downstream pathways:

• AMPK activation: MOTS-c translocates from mitochondria to the nucleus in response to metabolic stress, where it activates AMPK. AMPK is a cellular energy sensor that, when activated, simultaneously inhibits anabolic processes that consume energy (fatty acid synthesis, gluconeogenesis, protein synthesis) and activates catabolic processes that produce energy (fatty acid oxidation, glucose uptake, mitochondrial biogenesis). AMPK activation is also a mechanism by which exercise produces its metabolic benefits, which explains the "exercise mimetic" framing of MOTS-c research.
• Improved glucose uptake: In skeletal muscle cells, MOTS-c enhances insulin-stimulated glucose uptake by increasing GLUT4 transporter translocation to the cell surface — a mechanism that is impaired in insulin resistance. This improvement has been demonstrated in both cell culture and mouse models.
• Folate cycle and one-carbon metabolism: Research by Lee et al. demonstrated that MOTS-c inhibits the folate cycle within the methionine pathway, leading to accumulation of AICAR (an AMPK activator). This represents a novel mechanism through which MOTS-c influences AMPK activity that is distinct from classical AMPK activators like metformin.
• Anti-inflammatory and anti-senescence effects: MOTS-c modulates NF-κB inflammatory signaling and has been shown in some models to reduce markers of cellular senescence — the accumulation of non-dividing but metabolically active "zombie cells" that are associated with aging and age-related disease.
• Neuroprotection: A 2025 Nature study expanded MOTS-c's documented actions into neuroprotection and pancreatic islet cell senescence. The neuroprotective findings suggest MOTS-c may reduce neurotoxic protein aggregation in cell models — a finding relevant to neurodegenerative disease research, though far from clinical validation.
• Exercise response regulation: Circulating MOTS-c levels rise acutely in humans in response to vigorous exercise, consistent with the hypothesis that MOTS-c is one of the molecular signals through which skeletal muscle communicates its metabolic status to other tissues — a function sometimes called a "mitokine."

The following potential benefits are based primarily on animal model and in-vitro research. Human clinical trial data is very limited. Evidence Level C: limited human evidence, moderate animal evidence.

• Improved insulin sensitivity: Animal models consistently show MOTS-c improving insulin-stimulated glucose uptake and reducing markers of insulin resistance. In aging mice, MOTS-c administration improved insulin sensitivity and reduced age-associated weight gain, even without caloric restriction. A small number of human studies have found correlations between lower circulating MOTS-c levels and insulin resistance, but interventional data in humans is sparse.
• Exercise mimetic effects: In mice given MOTS-c, researchers observed improvements in running capacity, skeletal muscle glucose metabolism, and mitochondrial function — outcomes that parallel exercise-induced adaptations. Whether equivalent effects occur in humans at practical doses is unknown.
• Reduced metabolic dysfunction with aging: Older animals given MOTS-c showed improvements in multiple markers of metabolic aging — better glucose homeostasis, less age-related fat accumulation, improved physical function. These observations are suggestive but have not been replicated in controlled human trials.
• Neuroprotective effects (preliminary): Emerging research (2025) suggests MOTS-c may reduce markers of neurotoxic aggregation in cell models and affect pathways relevant to neurodegenerative disease. This is early-stage and does not constitute evidence of benefit in human neurodegenerative conditions.
• Pancreatic islet cell health: The 2025 Nature study reported that MOTS-c affects senescence pathways in pancreatic islet cells — the insulin-producing cells of the pancreas. Reduced islet cell senescence may protect beta-cell function with aging and in conditions that stress the pancreas. Again, this is preclinical evidence.

Human safety data for MOTS-c as an administered therapeutic is very limited. No published Phase 1 or Phase 2 clinical trials for MOTS-c as a therapeutic intervention have been identified as of April 2026.

• No established human safety profile: The absence of human clinical trial data means MOTS-c's safety in humans — across doses, administration schedules, and populations — has not been systematically characterized. This is a fundamental limitation.
• Animal safety data: Preclinical studies in mice have not identified major organ toxicity at studied doses. However, mouse pharmacokinetics and safety may not translate to humans.
• Injection site reactions: Subcutaneous injection of peptides in general is associated with local reactions (pain, redness, mild swelling). These are expected with any injectable peptide.
• Theoretical concerns: AMPK activation across multiple tissue types, if sustained, could theoretically affect anabolic processes including muscle protein synthesis. The implications of long-term MOTS-c administration for muscle mass are not characterized. Additionally, effects on cancer cell metabolism (AMPK has complex roles in cancer biology) are not established.
• Purity and product quality risk: Given that MOTS-c is currently in a regulatory grey area and not available from licensed pharmacies, any product obtained outside of research settings carries significant product quality uncertainty — contamination, incorrect peptide sequence, incorrect dosing, and unsterile preparation all represent serious risks.

Disclaimer: MOTS-c has no established therapeutic dose in humans. No clinical trial has validated a dose, dosing schedule, or route of administration for any human health indication. The following is a description of doses used in animal research, provided strictly for educational context.

Typical mouse study doses range from 5–15 mg/kg of body weight administered intraperitoneally or subcutaneously, often daily or several times per week. Translating animal doses to humans requires significant extrapolation and is not supported by PK/PD data in humans.

Research community discussions reference doses in the range of 5–10 mg subcutaneously several times per week, but these are entirely anecdotal and have no clinical validation behind them. They should not be interpreted as safe or effective doses for any individual.

MOTS-c research is almost entirely preclinical as of April 2026. The key published findings include:

• Lee et al. 2015 (Cell Metab): The discovery paper identified MOTS-c as encoded in mitochondrial DNA and demonstrated that MOTS-c administration in mice reduced obesity, improved insulin resistance, and extended healthy aging markers. This paper established the foundational biology.
• Reynolds et al. 2021 (Nat Commun): Showed that circulating MOTS-c levels rise in humans during vigorous exercise and that MOTS-c administered to aging mice improved muscle function and physical capacity — supporting the "exercise mimetic" hypothesis.
• Kim et al. 2022 (Cell Metab): Identified the folate cycle inhibition mechanism by which MOTS-c activates AMPK — a novel pathway distinct from metformin. This paper clarified how MOTS-c influences energy metabolism at the molecular level.
• Cobb et al. 2016 (Physiol Rep): Observed that circulating MOTS-c levels in humans decline with age and are inversely associated with insulin resistance — establishing the epidemiological rationale for interest in MOTS-c as both a biomarker and therapeutic target.
• 2025 Nature study: Expanded MOTS-c's documented preclinical actions into neuroprotection and pancreatic islet cell senescence — findings that broadened its research profile beyond metabolic regulation. Still preclinical.

Evidence classification: Level C — limited human interventional evidence, moderate animal model evidence. No completed Phase 1 or Phase 2 human trials have been published as of April 2026.

MOTS-c's regulatory status as of April 2026 is in transition. Understanding the distinction between what has been announced and what has been formally implemented is important.

• Current FDA status (Category 2): MOTS-c was classified by the FDA as a Category 2 substance, meaning it is not eligible for compounding by licensed compounding pharmacies in the United States. This classification has been in effect and means MOTS-c cannot be legally compounded or dispensed through licensed pharmacies under current rules.
• February 27, 2026 announcement: On February 27, 2026, Secretary of Health and Human Services Robert F. Kennedy Jr. announced on the Joe Rogan Experience podcast (Episode #2461) that approximately 14 peptides — including MOTS-c — would be moved from Category 2 back to Category 1 (eligible for compounding). This announcement generated significant attention in the research and clinical community.
• Formal rule change: pending as of April 14, 2026: The announcement by Secretary Kennedy was not itself a formal regulatory action. As of April 14, 2026, the FDA has not published a formal update to the Category 1 compounding list that reflects this announcement. The Pharmacy Compounding Advisory Committee (PCAC) has not completed its formal review of the affected substances, and the change has not been published in the Federal Register. The formal rule change is anticipated but not yet effective.
• Practical implication: MOTS-c is not currently legally available through licensed U.S. compounding pharmacies. The announced reclassification — if and when formally implemented — would change this. Individuals in clinical settings should monitor FDA regulatory publications (FDA.gov) for the formal update.
• Research use: Academic and institutional research use of MOTS-c is subject to standard institutional review board (IRB) and controlled substance protocols, where applicable.